Alector, Inc. Deferred Revenue Recognized
Alector, Inc. (ALEC) reported Deferred Revenue Recognized of $8.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-02-25
- Alector, Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-09-30 was $179.80M.
- Alector, Inc. contract with customer, liability, revenue recognized for the quarter ending 2021-03-31 was $4.10M.
- Alector, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $8.90M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|
| 2025-12-31 | $8.90M 10-K · filed 2026-02-25 | ||
| 2021-09-30 | $179.80M 10-Q · filed 2022-11-08 | $179.80M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $4.10M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |